Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)

• Status: Completed
• Trial end date: 2007-01-28
• Target enrollment: 0
• Participant gender: All

Summary

The object of the study is to determine whether different doses of SCH 530348, when added to standard medical care in persons undergoing percutaneous coronary intervention, will increase the risk of bleeding.

A secondary objective is to determine whether patients treated with SCH 530348 have fewer cardiac events such as heart attack, bypass surgery, or death compared with those persons treated with the standard of care.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Platelet Aggregation Inhibitors; Vorapaxar

Criteria

Inclusion Criteria:

• A person who is 45 years or older and is mentally competent to provide a signed written informed consent.

• A person who is scheduled to undergo a percutaneous coronary intervention or a heart catheterization with the intent to undergo a percutaneous coronary intervention.

• If a woman is of childbearing potential (ie, before menopause), she must test negative for pregnancy and agree to use a reliable method of birth control.

Exclusion Criteria:

• Pregnancy

• Recent stroke

• Active internal bleeding or a history of a bleeding disorder

• Increased risk of bleeding

• Severe high blood pressure

• Liver or kidney disease

• Low platelet count

• Condition such as alcoholism, mental illness, or drug dependence

• Ongoing chest pain

• Planned or ongoing treatment with a blood thinning medication

• A serious condition or illness that would interfere with participation in the study